Xavier Ramnik 4
4 · MoonLake Immunotherapeutics · Filed Jun 7, 2024
Insider Transaction Report
Form 4
Xavier Ramnik
Director
Transactions
- Award
Option to Buy
2024-06-06+7,688→ 7,688 totalExercise: $42.44Exp: 2034-06-06→ Class A ordinary shares, par value $0.0001 per share (7,688 underlying)
Footnotes (1)
- [F1]This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.